MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company's investigational new drug (IND) application to proceed for its phase 1 clinical trial for type 1 diabetes (T1D) therapy SAB-142. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progressio ...